Loading organizations...
Loading organizations...
De Novo Dairy is a technology company.
De Novo Foodlabs develops nature-identical functional proteins through its proprietary precision fermentation technology, offering advanced nutritional solutions. The company's primary innovation is NanoFerrin™, a sustainable, animal-free alternative to lactoferrin, which delivers health benefits for gut, immune, and cognitive function. Utilizing a biopharma discovery model and machine learning, De Novo Foodlabs optimizes the development and scalable production of these protein-based ingredients for widespread use.
The company was co-founded by Jean Louwrens, Leah Bessa, Richard Grieves, and Joni Symon. Their insight stemmed from a shared vision to create a more sustainable and ethical food system, addressing the challenge of sourcing valuable nutrients through traditional methods. With diverse backgrounds spanning business, food science, engineering, and biochemistry, the founders combined their expertise to leverage biotechnology for positive global impact.
De Novo Foodlabs targets Food & Beverage and nutrition companies seeking to enhance their product offerings with high-quality, sustainably produced ingredients. The company's long-term vision is to elevate human health and well-being by revolutionizing how nutrients are produced and consumed, fostering a healthier future for both individuals and the planet through scientific innovation in functional ingredients.
De Novo Dairy has raised $1.5M across 1 funding round.
De Novo Dairy has raised $1.5M in total across 1 funding round.
De Novo Dairy has raised $1.5M in total across 1 funding round.
De Novo Dairy's investors include Blaine Vess.
De Novo Dairy (now evolved into De Novo Foodlabs) is a South Africa-based food tech company pioneering precision fermentation to produce animal-free, nature-identical dairy proteins, starting with high-value immune-regulating proteins like lactoferrin for infant nutrition and personalized health products.[1][2][3][4] It serves B2B partners globally, such as established brands in infant formula and functional foods, solving the problem of inconsistent, costly, and ethically challenging supply of bioactive dairy proteins from animal sources—essential for human nutrition where plant alternatives fall short.[1][2][5] The company has raised about $4 million in seed funding from investors like UM6P Ventures, Big Idea Ventures, Joyful Ventures, and others, fueling commercialization of its flagship NanoFerrin™ lactoferrin, with initial launches targeted in Africa and expansion to the US.[2][3]
Growth momentum includes securing seed investments in 2022, establishing offices in Cape Town and Raleigh, North Carolina, and advancing a proprietary yeast platform for scalable production of proteins like NanoFerrin, which boosts gut health and immunity at lower costs than bovine-derived versions.[2][3][4]
De Novo Dairy was co-founded by Jean Louwrens (CEO) and Leah Bessa, who initially launched Gourmet Grubb to modernize insects as a sustainable protein source for dairy alternatives, reflecting their passion for ethical, Africa-centric nutrition solutions.[3][6] The idea evolved as they recognized limitations in insect proteins and pivoted to precision fermentation—"de novo" meaning "from new," enabling animal-free creation of functional human milk proteins critical for infant health, where African consumers prioritize nutritional superiority over plant-based shifts.[1][3][6]
Early traction came from being Africa's first precision fermentation player, backed by grants and investors like Big Idea Ventures and Kale United; a pivotal 2022 seed round from UM6P Ventures accelerated their first product toward launch, building on prior manufacturing networks from founders' ventures.[2][3][6]
De Novo rides the precision fermentation wave in alt-protein tech, disrupting a $61.6bn infant nutrition market (projected CAGR 7.7% to 2026) by addressing gaps in bioactive proteins amid rising demand for sustainable, ethical dairy alternatives.[1] Timing aligns with global pushes for food security in Africa—lower R&D costs enable faster innovation—while countering plant-based limitations in nutrition-dense proteins, similar to players like Perfect Day (whey) or Formo (cheese).[1][2]
It influences the ecosystem by pioneering African biotech, attracting VC to the continent, and enabling brands to fortify products with scalable, immune-regulating ingredients, potentially accelerating personalized nutrition amid climate-driven agriculture strains.[2][3][4]
De Novo Foodlabs is poised to launch NanoFerrin commercially in Africa soon, scale production via its yeast platform, and enter US markets with $4M fueling global B2B partnerships—potentially expanding to full protein portfolios for life-stage nutrition.[2][3][6] Trends like precision ag-tech growth, African foodtech investment, and demand for non-animal bioactives will propel it, evolving its influence from regional disruptor to key supplier in sustainable dairy ecosystems. This positions De Novo to deliver ethical, high-impact nutrition at scale, fulfilling its "from new" promise for healthier futures.[1][3]
De Novo Dairy has raised $1.5M across 1 funding round. Most recently, it raised $1.5M De Novo Foodlabs - Seed in August 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 23, 2024 | $1.5M De Novo Foodlabs - Seed | Blaine Vess |